FDA delays approval of Spectrum Pharma's drug due to COVID-19
Oct 26 (Reuters) - Spectrum Pharmaceuticals SPPI.O said on Monday the U.S. Food and Drug Administration has deferred approval of its experimental drug for treating chemotherapy induced loss of white blood cells in cancer patients, due to COVID-19 related travel restrictions.
The decision was taken as the U.S. health agency was unable to conduct an inspection of company's South Korea-based manufacturing plant, required before drug approval, due to restrictions on travel related to the COVID-19 pandemic.
(Reporting By Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
((email@example.com; within U.S. +1 646 223 8780, outside U.S. +91 806749 8325;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
In This StorySPPI
Latest Markets Videos
- White House says Walmart, FedEx, UPS to work 24/7 to ease supply bottlenecks for holiday season
- Chinese online brokers Futu and UP Fintech face regulatory risks - People's Daily website
- September, Third Quarter 2021 Review and Outlook
- PRECIOUS-Gold eases as inflation data fans policy tightening bets